weight loss drugs that are not glp 1 GLP-1: Genetic Variants Related to GLP-1 RA Medications The GLP-1 revolution: What UAB

Dichotomous data was extracted to calculate RRs

tirzepatide is contraindicated in individuals with personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia type 2 syndromes (54, 61)

Many commercial health plans and employer-sponsored benefit programs either exclude anti-obesity medications from formularies entirely or place them on higher cost-sharing tiers, resulting in limited or no insurance coverage for patients, even when clinically appropriate

Americas Weight-Loss Fixation Is Driving Massive Growth Industry consultancy firm Grand View Research forecasts the GLP-1 drug market to grow by a compound annual growth rate of 18.54% between 2024 and 2030, resulting in a global market value increase from $13.84 to $48.84 billion

This is why injectable GLP-1 medications produce such dramatic effects on appetite and weight